Latest News & Features
Americas
Amgen alleges infringement by proposed biosimilar versions of Prolia and XGEVA | Complaint accuses Samsung of failing to fully disclose biosimilar application and seeks injunction on bone-treatment products. 15 August 2024
Americas
AstraZeneca successfully argued that “no reasonable jury” could find it had infringed the patents-in-suit claiming lung cancer patents | Reprieve comes after misconduct allegations against a Pfizer unit fell flat earlier this month. 15 August 2024
Big Pharma
Delaware judge denies pharma giant’s request for injunction on rivals’ generic of Entresto | Novartis ‘unlikely to succeed’ in proving infringement | Lawsuit is one of several attempts to preserve exclusivity of the drug ahead of patent expiry and US price caps. 13 August 2024
Americas
Litigator brings extensive courtroom experience and advises clients on how to navigate disputes through federal courts, state courts, and arbitrations. 13 August 2024
Americas
Swiss biopharma took preemptive legal action against US rival after learning it would be subject to “aggressive” enforcement over therapy | Technology at heart of case treats disruptions to healthy bacterial organisms in human intestinal tract. 13 August 2024
Americas
A Delaware jury found AstraZeneca liable for induced infringement of a cancer treatment in May | Pharma company levelled allegations of "unclean hands" and "patent misuse" at Pfizer unit. 8 August 2024
Careers
The firm adds three partners to its New York office | Expansion brings a combined 60 years of experience | Hires experienced in high-stakes patent disputes involving biologics, small-molecule drugs, and medical devices. 8 August 2024
Americas
District court partially grants Ultrahuman Healthcare's motion to stay patent litigation with Oura Health, pending an ITC investigation | Court's order pauses several patent claims | Decision allows Oura's copyright allegations to proceed independently. 6 August 2024
Americas
Big pharma subsidiary and Japanese collaborator allege infringement of blockbuster drug product | $1.2 billion treatment developed by University of California. 6 August 2024
Americas
Pharma company argues that affirming lower court’s decision would shrink Orange Book “dramatically” | District court found Teva’s patents do not claim the drug product for which they are listed. 1 August 2024